New cancer treatment shows promise in treating multiple myeloma
A new cancer treatment developed by Hadassah University Medical Center in Israel has shown a remarkable 90% success rate in treating multiple myeloma, an incurable type of cancer.
The treatment, called CAR-T cell therapy, utilizes the patient’s own immune system to target and destroy cancer cells. In a study of 74 patients, 90% achieved remission after receiving the treatment.
CAR-T cell therapy is a type of immunotherapy, which means that it works by boosting the body’s own immune system to fight cancer. In CAR-T cell therapy, the patient’s T cells are collected and genetically modified to express a chimeric antigen receptor (CAR). This receptor allows the T cells to recognize and bind to cancer cells. Once the T cells bind to cancer cells, they release proteins that kill the cells.
CAR-T cell therapy is still in the early stages of development, but it has the potential to revolutionize cancer treatment. The treatment is expected to become available in the United States within a year, following clinical trials and FDA approval.
The development of CAR-T cell therapy is a major breakthrough in cancer treatment
This treatment has the potential to offer hope to patients with multiple myeloma and other types of cancer that have been previously considered incurable.
Some details about the Cancer treatment
- The treatment is personalized, meaning that it is tailored to each individual patient.
- The treatment is typically given as an infusion.
- The treatment can have side effects, including cytokine release syndrome (CRS) and neurotoxicity.
- The treatment is expensive, but it is likely to become more affordable as it becomes more widely available.
Related posts:
